News Forum

PSYCHOLOGICAL DISTRESS AFTER PROSTATE CANCER TREATMENT
Ream E, Quennell A, Fincham L et al. Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer advance online publication 2008, 1-7, doi:10.1038/sj.bjc.6604406

Men treated for prostate cancer have high levels of psychological distress and many experience continuing sexual dysfunction and lower urinary tract symptoms, according to a survey of men in England designed to explore their supportive care needs.

Prostate cancer is the most common solid cancer in men, accounting for one in every four cancers diagnosed in males in England in 2004. Fortunately, the survival rate is improving, reflecting its slow-growing nature and its successful treatment in many men. Nearly three-quarters (71 per cent) of men are still alive five years after being diagnosed with prostate cancer.

Therapeutic options include surgery, radiotherapy and hormonal treatments, with the choice determined by the patient's age, cancer stage and comorbidities. Some treatments can have long-term effects on sexual and urological function.

The primary aim is to optimise cancer control, but some doctors take into account the patient's urological and sexual function before treatment and their views on the balance of treatment efficacy against side-effects.

In this study, researchers surveyed men with prostate cancer in six areas of England. They invited 1,848 men diagnosed with prostate cancer in the previous three to 24 months to take part. Those who replied (820) were sent a postal questionnaire asking about supportive care needs, prostate symptoms, quality of life, their cancer and its treatment; 741 were returned.

Three-quarters of the men taking part in the survey were aged 65 years or more; 51 per cent had hormonal therapy, 25 per cent, radical prostatectomy, and 28 per cent, radiotherapy to the prostate. Just under half (46 per cent) of the men said that their cancer was in remission.

The survey revealed that these patients had significant unmet supportive care needs. The areas of greatest need were related to psychological distress, problems with sexuality and the management of enduring lower urinary tract symptoms.

Men who were uncertain of their remission status had higher levels of psychological need, while those not in remission were more likely to need information. Nearly 30 per cent reported moderate or extreme anxiety or depression. A similar number had difficulty with undertaking usual activities. Pain was reported by 26 per cent and 22 per cent had mobility problems.

Virtually all (97 per cent) of the men reported that in the month before the survey, they had experienced lower urinary tract symptoms, including frequency or needing to urinate at night. Urinary symptoms were affected by treatment, remission status and time since last treatment. They were least severe in men who were in remission, in those who had undergone radical prostatectomy and/or in those who had completed their treatment 19-24 months before the survey. Unmet needs related to sexuality were more common in younger men and in those who had undergone radical prostatectomy.

The researchers concluded that the need for systematic assessment and better management of psychological distress in men with prostate cancer was evident, with high levels of distress identified in the sample, even though the majority had completed treatment more than a year ago. They added that sexual dysfunction and lower urinary tract system symptoms also required greater attention by prostate services.

GUM DISEASE AND CANCER RISK
Michaud DS, Liu Y, Meyer M et al. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol 2008; 9: 550-8.

A large prospective cohort study has revealed a link between gum disease and the risk of developing cancer. The study showed that participants with periodontal disease had a 14 per cent increased risk of cancer compared with volunteers without periodontal disease.

The reasearchers analysed data from the Health Professionals Follow-Up study, which involved 51,529 US male health professionals aged 40-75 years and asked participants to report on baseline gum disease with bone loss, number of natural teeth and tooth loss in the past two years. Follow-up questionnaires collected data on any new cancer diagnoses every two years.

Results showed that 40,512 participants had no history of periodontal disease, while 7,863 did. During average follow-up of 17.7 years, 5,720 cancer cases were reported. The five most common cancers were colorectal (1,043), melanoma of the skin (698), lung (678), bladder (543) and advanced prostate (541).

After adjusting for smoking, dietary factors and other known risk factors, researchers found that participants with a history of gum disease were 14 per cent more likely to develop any type of cancer compared to those with no history of gum disease. Furthermore, compared to men with healthy gums, men with a history of gum disease were 49 per cent more likely to develop kidney cancer, 36 per cent more likely to develop lung cancer, 54 per cent more likely to develop pancreatic cancer and 30 per cent more likely to develop haematological cancers.

The researchers said that their findings need confirmation, but suggested that periodontal disease might be a marker of a susceptible immune system, or might directly affect cancer risk, adding that the study was limited by self-reports of periodontal disease and by inadequate power to study less common cancers. Its findings might also not apply to women.

Summaries provided by the European School of Oncology's Cancer Media Service .


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases